Cargando…
Role of the PD-1 and PD-L1 axis in COVID-19
Severe COVID-19 patients display dysregulated expression of checkpoint molecules PD-1 and its ligand PD-L1, suggesting that these checkpoint molecules could be considered as prognostic markers and therapeutic targets in severe cases of COVID-19.
Autores principales: | R Bonam, Srinivasa, Hu, Haitao, Bayry, Jagadeesh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Medicine Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9332906/ https://www.ncbi.nlm.nih.gov/pubmed/35899493 http://dx.doi.org/10.2217/fmb-2022-0103 |
Ejemplares similares
-
IFN-γ Induces PD-L1 Expression in Primed Human Basophils
por: Bonam, Srinivasa Reddy, et al.
Publicado: (2022) -
THEME: “Vaccines and Vaccine Adjuvants/Immunomodulators for Infectious Diseases”
por: Retnakumar, Sruthi Vijaya, et al.
Publicado: (2023) -
Wnt-β-Catenin Signaling in Human Dendritic Cells Mediates Regulatory T-Cell Responses to Fungi via the PD-L1 Pathway
por: Karnam, Anupama, et al.
Publicado: (2021) -
Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients
por: Bonam, Srinivasa Reddy, et al.
Publicado: (2020) -
Progress and Challenges in the Use of MAP1LC3 as a Legitimate Marker for Measuring Dynamic Autophagy In Vivo
por: Bonam, Srinivasa Reddy, et al.
Publicado: (2020)